linjc16/ctgov huggingface dataset:
Reversibility of Minimal Hepatic Encephalopathy Following Liver Transplantation

Study Overview
=================
Brief Summary
-----------------
This study included 20 patients listed for liver transplantation in addition to 20 age- and sex- matched controls. Neurological, psychiatric, laboratory and radiological examinations were performed for both patients and controls before and 6 months after liver transplantation. Assessment of cognitive functions by Trail Making Test A (TMT A), TMT B, Digit Symbol Test (DST), and Serial Dotting Test (SDT) was done before and after liver transplantation.

Conditions
-----------------
Minimal Hepatic Encephalopathy

Intervention / Treatment
-----------------
* Procedure: Liver transplantation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Right handed patients with biopsy-proven liver cirrhosis listed for liver transplantation Exclusion Criteria: Overt hepatic encephalopathy. Significant cortical atrophy or other structural brain changes revealed by conventional neuro-imaging. Regular use of psychotropic drugs, such as benzodiazepines. Known major psychiatric disorder. Less than 6 months of complete alcohol abstinence. Post-transplant toxic levels of immunosuppressive drugs. Patients unable to perform the tests (Illiterate or upper limb motor handicaps).

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 55 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Patient Group<br>Twenty right handed patients with biopsy-proven liver cirrhosis listed for liver transplantation. | Procedure: Liver transplantation<br> <br> |
| Control Group<br>Twenty age-matched healthy persons. They were similar to the patient group in respect to the number of education years, sex, and handedness. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Improvement of Psychometric tests. |  | 6 months following liver transplantation. | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Improvement of liver functions and MELD score following liver transplantation. |  | 6 months following liver transplantation. |
Study Of Asthma In Patients Of African Descent

Study Overview
=================
Brief Summary
-----------------
This study will last up to 62 weeks. You will visit the clinic up to 17 times. Certain clinic visits will include physical examination, medical history review and lung function tests. The purpose of this study is to see if one asthma drug (fluticasone propionate/salmeterol) is better in reducing the number of asthma exacerbations compared with another drug (fluticasone propionate alone)

Official Title
-----------------
A Multicenter, Randomized, Double-Blind, Parallel Group, 52-Week Comparison of Asthma Control and Measures of Airway Inflammation in Subjects of African Descent Receiving Fluticasone Propionate/Salmeterol 100/50mcg DISKUS® BID or Fluticasone Propionate 100mcg DISKUS® BID Alone

Conditions
-----------------
Asthma

Intervention / Treatment
-----------------
* Drug: fluticasone propionate/salmeterol powder
* Drug: fluticasone propionate powder


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion criteria: History of asthma for at least 6 months. Taking a low-dose of an inhaled corticosteroid for at least one month prior to the study (such as fluticasone propionate or budesonide). Exclusion criteria: History of life-threatening asthma. Hospitalized for asthma within 3 months prior to the study. Current respiratory tract infection. Will not be able to attend clinic visits for the entire length of the study. Certain medical conditions that will make being in the study unsafe (such as congestive heart failure, uncontrolled hypertension, tuberculosis or certain drug allergies).

Ages Eligible for Study
-----------------
Minimum Age: 12 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: fluticasone propionate/salmeterol powder|nan|
|Drug: fluticasone propionate powder|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Asthma exacerbation rate per patient per year |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Morning peak flow measurement, percent of asthma symptom-free days, percent of albuterol-free days |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
asthma exacerbation, asthma
Correlation Between Aqueous Protein Level and Clinical Grading of Flare and Flaremetry.

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to compare flaremetry readings with the protein content of the aqueous humor and the clinical grading of flare.

Detailed Description
-----------------
A total of 20 patients will be included. 10 patients with uveitis and 10 control patients scheduled for phacoemulsification. Each patient will undego complete ophthalmic examination and clinical biomicroscopic grading of the anterior chamber flare applying the SUN working group grading system. Aqueous specimens will be obtained by anterior chamber paracentesis for protein analysis. Each Patient will undego paracentesis and 0.2 ml of aqueous will be obtained. The aqueous sample will be stored at -70°C until the time of analysis for protein content. Objective assessment of flare will be done.

Official Title
-----------------
Correlation Between Aqueous Protein Level and Clinical Grading of Flare and Flaremetry.

Conditions
-----------------
Uveitis

Intervention / Treatment
-----------------
* Procedure: Paracentesis of the anterior chamber


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 10 patients with uveitis with cataract 10 patients without uveitis with cataract Inactive inflammation for at least 3 months Exclusion Criteria: Infectious uveitis endophthalmitis cases with corneal scar

Ages Eligible for Study
-----------------
Minimum Age: 10 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: patients with uveitis<br>Paracentesis of the anterior chamber in Paients with uveitis undergoing cataract surgery | Procedure: Paracentesis of the anterior chamber<br>* Aqueous humor parenthesis for quantitative protein analysis in patients with and without uveitis.<br>|
| Experimental: patients without uveitis<br>Paracentesis of the anterior chamber in patients without uveitis undergoing routine cataract surgery | Procedure: Paracentesis of the anterior chamber<br>* Aqueous humor parenthesis for quantitative protein analysis in patients with and without uveitis.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| compare flaremetry readings with the protein content of the aqueous humor | Compare flaremetry readings with the protein content of the aqueous and the clinical grading. | one month | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
flaremetry, aqueous proteins, clinical grading, Compare flaremetry readings with the protein content of the aqueous, Compare flaremetry readings with clinical grading of flare
Epithelioid Hemangioma of Bone And Soft Tissue

Study Overview
=================
Brief Summary
-----------------
The controversy surrounding epithelioid hemangioma diagnosis stems from its somewhat aggressive clinical characteristics, including multifocal presentation and occasional lymph node involvement. The investigators reviewed the clinicopathologic and radiologic characteristics of bone and soft tissue epithelioid hemangioma in patients treated at our institution with available tissue for molecular testing. The hypothesis is that epithelioid hemangioma may present with multifocal involvement and rare loco-regional lymph node metastasis, but it remains a benign tumor with excellent prognosis.

Detailed Description
-----------------
The investigators retrospectively reviewed patients treated for epithelioid hemangioma of the bone and soft tissue in a single insitution. The purpose of this study is to evaluate the pathological, clinical, and radiological characteristics of epithelioid hemangioma arising within bone and soft tissue, in the first cohort of cases where the definitive diagnosis is supplemented by molecular techniques. The hypothesis is that the improved knowledge regarding this rare entity can more definitively elucidate the benign biology of epithelioid hemangioma.

Official Title
-----------------
Epithelioid Hemangioma of Bone And Soft Tissue: a Benign Tumor With Metastatic Potential

Conditions
-----------------
Epithelioid Hemangioma of Bone, Epithelioid Hemangioma

Intervention / Treatment
-----------------
* Procedure: Surgery


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients with epithelioid hemangioma of bone and soft tissue in the extremities and pelvis Exclusion Criteria: patients with epithelioid hemangioma of bone and soft tissue in the spine
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: Surgery|Patients affected by epithelioid hemangioma treated with surgery|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Multifocal presentation of patients with epithelioid hemangioma of bone and soft tissue without producing a fatal outcome | The investigators defined multifocal presentation the presence of secondary lesions by imaging at presentation of the disease or during follow-up. | 2 years |
Nutrient Mixtures and Neurodevelopment

Study Overview
=================
Brief Summary
-----------------
Background: Adequate levels of beneficial nutrients are important for neurodevelopment. Although, nutrients are ingested in combination, considering nutrients as a mixture has not been studied with respect to health, such as neurodevelopment. Objective: To examine the impact of prenatal and childhood nutrition mixtures on neurodevelopment. Design: Participants included mother-child pairs in the Programming Research in Obesity, Growth Environment and Social Stress (PROGRESS) prospective birth cohort in Mexico City. Prenatal and child nutrition profiles were assessed among 65 and 329 children respectively by analyzing components of a food frequency questionnaire. Child neurodevelopmental outcomes at 4-6 years of age were measured using the McCarthy Scales of Children's Abilities (MSCA).

Official Title
-----------------
Prenatal and Childhood Nutrient Mixtures Predict Neurodevelopmental Outcomes Among Children in Mexico City

Conditions
-----------------
Neurodevelopment

Intervention / Treatment
-----------------
* Other: Nutrient mixtures


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Women of children: less than 20 weeks gestation at the start of the study at least 18 years of age and planned to reside in Mexico City for the next three years. Exclusion Criteria: Women of children: free of heart or kidney disease not use steroids or anti-epilepsy drugs not consume alcohol.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 44 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Subset from PROGRESS cohort<br>Participants included children 4-6 years of age from mother-child pairs in the Programming Research in Obesity, Growth Environment and Social Stress (PROGRESS) prospective birth cohort in Mexico City | Other: Nutrient mixtures<br>* consumption of a mixture of beneficial nutrients<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| McCarthy Scales of Children's Abilities (MSCA) | The MSCA consists of 18 short sub-tests that are weighted and combined to yield five scale scores or indexes - verbal, perceptual performance, quantitative, memory and motor - as well as an overall general cognitive index based on the first three scaled indexes. The McCarthy Scale index scores can range from 22 - 78 with higher index scores indicating better outcome. | at age 4 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Nutrition, Nutrients, Mixtures, Neurodevelopment, Prenatal, Children
Erythema Toxicum Neonatorum in Newborns and the Development of Asthma

Study Overview
=================
Brief Summary
-----------------
Erythema Toxicum Neonatorum (ETN) is a common skin finding that affects healthy full-term babies. Several authors have commented on the possible relationship between ETN and the development of atopic conditions, such as atopic dermatitis or respiratory disease later in life. There is a paucity of research addressing this issue.

Official Title
-----------------
The Implication of Erythema Toxicum Neonatorum in Newborns on the Development of Future Asthma

Conditions
-----------------
Asthma, Erythema Toxicum Neonatorum

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Children between the ages of 3-9 years who have had at least 2 asthma diagnoses within the last 2 years. Control subjects will be age matched and without an asthma diagnosis. Exclusion Criteria: Children without accessible medical records

Ages Eligible for Study
-----------------
Minimum Age: 3 Years
Maximum Age: 9 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
The Role of Unsteady Wall Shears Stress Stimuli on Human Umbilical Vein Endothelial Cells Harvested From Umbilical Cords

Study Overview
=================
Brief Summary
-----------------
The aim of this study is to obtain and test endothelial cells (EC's) from umbilical cords to examine specific properties of these cells which make up the inner lining of blood vessels.

Detailed Description
-----------------
Mechanical testing will be performed on the Ec's to see how the cells reacts and ultimately how the blood vessel is affected. A central role in the mechanism that defines the nature of vessel remodelling is played by endothelial cells. EC's are extremely sensitive to the frictional forces exerted on a unit of the endothelial area by blood flow. This mechanical stimulus is known as wall shear stress (WSS). WSS experienced by EC's in-vivo is unsteady due to the unsteady nature of blood flow produced during the cardiac cycle and due to the complex nature of the vascular tree. The extent to which this applies to venous cells and tissue remains unknown and it is the focus of this study.

Official Title
-----------------
The Role of Unsteady Wall Shears Stress Stimuli on Human Umbilical Vein Endothelial Cells (HUVECs) Harvested From Umbilical Cords

Conditions
-----------------
Vascular Diseases

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients who are attending the Maternity Services who are pregnant and due for routine delivery. Aged 18- 40 years. Are willing and capable to voluntarily sign a statement of informed consent to take part in this investigation. Patients due to give birth to twins will be included in this study. Women having both normal delivery and caesarean section delivery will be included in this study. Exclusion Criteria: Patients unable to provide informed consent. Patients who are under the age of 18 and over the age of 40 years. Patients who are deemed unsuitable due to any circumstances as deemed appropriate by the Consultant. Patients with a Blood Borne Virus (HIV Type 1, HIV Type 2, Hepatitis B, Hepatitis C) will be excluded from the study. Patients with diabetes that is not gestational in nature will be excluded from this study. Patients due to deliver triplets or more will be excluded from this study. Patients who deliver their baby before 37 weeks gestation will not have umbilical cord tissue retained for study purposes.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 40 Years

Sexes Eligible for Study
-----------------
Female

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The identification of Endothelial Cell phenotype | To identify this phenotype by assessing the endothelial identity markers, the endothelial to mesenchymal transition markers and the regulation of genes involved in EC quiescence. | 2 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Endothelial Cells
Study Evaluating Bazedoxifene/Conjugated Estrogens Combinations in Fed and Fasting in Healthy, Postmenopausal Women

Study Overview
=================
Brief Summary
-----------------
The primary objective is to determine the effect of a high-fat meal on the bioavailability and PK of a single, oral dose of BZA/CE (PNP) 20mg/0.625 strength tablet, assessing both the BZA and CE components.

Official Title
-----------------
An Open-Label, Single-Dose, 3-Period, Crossover Study To Determine The Effect Of A High-Fat Meal On The Relative Bioavailability And Pharmacokinetics Of A Single Dose Of Bazedoxifene Acetate/Conjugated Estrogens (Premarin© New Process) Administered Orally To Healthy, Postmenopausal Women

Conditions
-----------------
Healthy

Intervention / Treatment
-----------------
* Drug: Bazedoxifene/conjugated estrogens combination


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Healthy as determined by the investigator on the basis of history, physical examinations, clinical laboratory test results, vital signs, and 12-lead ECGs.

Ages Eligible for Study
-----------------
Minimum Age: 35 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Bazedoxifene/conjugated estrogens combination|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| PK parameters |  |  |
Novel Equation for Estimating Resting Energy Expenditure

Study Overview
=================
Brief Summary
-----------------
The energy and nutrition states are closely associated with CKD patients complications and outcomes.To reach the energy balance target, we need the accurate resting energy expenditure level of patients. Traditional equations are not applicable to CKD patients,so we aim to develop and validate a equation for estimating resting energy expenditure in CKD patients.

Official Title
-----------------
Novel Equation for Estimating Resting Energy(REE) Expenditure in Chronic Kidney Disease(CKD) 3-5 Stages Patients

Conditions
-----------------
Resting Energy Expenditure, Chronic Kidney Disease

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: CKD 3-5 stages Age:18-80 years old Exclusion Criteria: Dialysis and kidney transplantation; Acute complications to hospitalization 1 month prior to the study; Acute or chronic infections, cancer and other wasting diseases in the past year; Thyroid dysfunction; Acute onset of podagra; Musculoskeletal diseases; Respiratory diseases (asthma, pleural effusion, pneumothorax, COPD); History of hormonal drugs use; During pregnancy or lactation

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Novel equation development | Developed equation for estimating REE in CKD 3-5 stages patients | September 1, 2017 to June 1, 2018 | 
| Novel equation validation | Validate the noval equation with REE obtained by indirect calorimetry (IC). | June 1, 2018 to March 1, 2019 |